Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This is a clinical research study of a new investigational treatment for cancer called
"DTI-015" to be given by intratumoral injection. Intratumoral injection is when drug is
injected directly into the tumor. This study will help doctors find out what is the best dose
level for DTI-015 and if this treatment can shrink tumors without causing severe side
effects. The effects of the drug on the patient's quality of life (how the patient feels and
what the patient can do) and their mental functions (reasoning and thinking abilities) will
also be studied.